Stomatitis, a painful inflammation of the mucous membranes in the mouth, is a frequently encountered and debilitating side effect of chemotherapy. It complicates cancer treatment by impairing oral intake, diminishing quality of life, and sometimes forcing reductions or interruptions in chemotherapy dosing that can compromise overall therapeutic outcomes. Current treatment options, including chlorhexidine mouthwash, aim to reduce infection and inflammation but often carry side effects or only provide modest relief.

The clinical trial enrolled 70 cancer patients suffering from chemotherapy-induced stomatitis to evaluate whether Malva sylvestris mouthwash could offer enhanced symptom control. Participants were meticulously randomized into two groups: one receiving 15 ml of Malva sylvestris mouthwash thrice daily for 14 days, and the control group using standard chlorhexidine mouthwash under identical regimens. Importantly, the study was designed as triple-blind—meaning neither the patients, healthcare providers, nor outcome assessors knew the group assignments—thus ensuring unbiased assessment of outcomes.

Throughout the study, stomatitis severity and pain levels were precisely tracked using the World Health Organization’s Mucositis Scale and the Visual Analog Scale for pain, respectively. Measurements at baseline, day 3, day 7, and day 14 provided a comprehensive temporal profile of efficacy. Prior to intervention, both groups exhibited comparable baseline scores, reinforcing the validity of subsequent comparative analyses between the two treatment modalities.

By day 7, stark contrasts emerged. Patients in the Malva sylvestris group showed significantly reduced stomatitis severity and experienced less pain compared to their counterparts receiving chlorhexidine, with p-values indicating robust statistical significance (p < 0.001). These findings are particularly remarkable given the limited therapeutic arsenal currently available for mucositis management.

The trajectory of stomatitis improvement was also notably steeper in the intervention group. Statistical analysis revealed that not only did Malva sylvestris mouthwash reduce symptoms more effectively, but it also expedited healing progression compared to the control. This accelerated recovery timeline is critical for cancer patients, potentially facilitating sustained chemotherapy regimens without dose-limiting interruptions due to oral side effects.

By day 14, although both groups showed improvement, the difference in stomatitis severity between the Malva sylvestris and chlorhexidine groups narrowed and did not reach statistical significance (p = 0.08). Nevertheless, the overall trend favored the mallow-based mouthwash, hinting at persistent therapeutic benefits over the standard care period.

The bioactive compounds in Malva sylvestris, including mucilaginous polysaccharides, flavonoids, and phenolic acids, are believed to orchestrate its anti-inflammatory, antioxidant, and wound-healing properties. These bioactivities likely underpin the observed clinical benefits, representing a compelling example of traditional phytotherapy harnessed through rigorous clinical validation in modern medicine.

Importantly, the trial highlighted a favorable safety profile for the Malva sylvestris mouthwash. No adverse effects nor complications were reported, underscoring its potential as a low-risk adjunct or alternative for oral mucositis management. Given the vulnerability of cancer patients, such safety assurances are paramount in clinical decision-making.

The study’s triple-blind design and randomized methodology underscore its scientific rigor, minimizing bias and enhancing the reliability of findings. The use of internationally recognized assessment scales ensures that results are interpretable within the broader context of mucositis research.

These results have widespread implications for oncology practice worldwide. By integrating Malva sylvestris mouthwash into supportive care protocols, clinicians may improve patient comfort, reduce the burden of chemotherapy complications, and potentially mitigate costs associated with managing severe mucositis.

Future research directions include larger-scale multicenter trials and investigations into the mechanistic pathways by which Malva sylvestris exerts mucosal protection and pain reduction. Additionally, exploring its use across diverse cancer types and chemotherapy regimens could broaden its applicability.

This innovative trial paves the way for renewed interest in medicinal plant-based interventions, bridging ethnobotanical knowledge with contemporary clinical oncology. As the demand for safe and effective cancer supportive therapies grows, Malva sylvestris emerges as a promising candidate in the therapeutic landscape.

The study also illuminates the importance of holistic care approaches incorporating natural compounds with proven efficacy, epitomizing a modern renaissance in phytotherapy guided by evidence-based medicine.

In an era where cancer survival rates improve, quality of life considerations are paramount. Malva sylvestris mouthwash, as demonstrated by this research, holds considerable promise in addressing the challenging side effect of stomatitis, ultimately enhancing overall patient well-being during chemotherapy.

As scientific communities embrace such integrative treatments, patients stand to benefit from adjunctive therapies that are both efficacious and well-tolerated, marking a significant step forward in comprehensive cancer care.

This landmark trial indicates a future where the boundaries between traditional remedies and conventional medicine grow increasingly synergistic, offering patients novel solutions informed by both heritage and innovation.

Subject of Research:
Effectiveness of Malva sylvestris mouthwash in treating chemotherapy-induced stomatitis and associated pain.

Article Title:
The effect of Malva sylvestris mouthwash on chemotherapy-induced stomatitis and associated pain in patients with cancer: a triple-blind randomized clinical trial.

Article References:
Salmaninejad, Z., Mazhari, F., Pourhosseini, S. et al. The effect of Malva sylvestris mouthwash on chemotherapy-induced stomatitis and associated pain in patients with cancer: a triple-blind randomized clinical trial. BMC Cancer 25, 1695 (2025). https://doi.org/10.1186/s12885-025-15158-w

Image Credits: Scienmag.com

DOI: 10.1186/s12885-025-15158-w (Published 03 November 2025)

Chemotherapy has long been a cornerstone of cancer treatment, aimed at eradicating malignant cells and halting tumor progression. However, clinical outcomes have been inconsistent, with approximately 20 to 50% of patients showing resistance to commonly used chemotherapies. These patients often endure the toxic side effects without gaining any therapeutic benefits. Geoff Macintyre, heading the Computational Oncology Group at CNIO, highlights the critical need for predictive tools that can identify such non-responders early, thus allowing clinicians to adjust treatment plans more effectively.

The team, collaborating with the University of Cambridge and the biotech startup Tailor Bio, developed a computational model that leverages chromosomal instability patterns—complex genomic alterations characterized by variations in chromosome number and structure within tumor cells. Unlike traditional approaches that focus on single gene mutations or protein expressions, this method capitalizes on the unique signatures formed by pervasive chromosomal aberrations, enabling a broader and more reliable prediction of chemoresistance.

At the heart of the methodology is the identification of "signatures of chromosomal instability" (CIN), which encompass recurrent patterns of chromosome gains, losses, and rearrangements within malignant cells. These CIN patterns reflect fundamental disruptions in the tumor genome’s architecture, impacting how cancer cells respond to chemotherapeutic agents such as platinum compounds, taxanes, and anthracyclines. By quantifying these signatures through advanced computational algorithms, the researchers established robust biomarkers indicative of treatment resistance.

The study utilized an extensive dataset comprising genomic and clinical information from over 800 cancer patients diagnosed with diverse malignancies including breast, prostate, ovarian, and sarcoma cancers. Through a simulated trial framework, the researchers retrospectively analyzed patient responses to chemotherapy with respect to their tumor CIN profiles. The strong correlation between specific chromosomal instability signatures and chemotherapy outcomes validated the predictive power of the test and underscored its potential for broad clinical application across multiple cancer types.

This innovative approach marks a significant departure from conventional oncology paradigms. Traditionally, chemotherapy regimens have been prescribed based on histological cancer types and clinical staging, without deep molecular stratification. The introduction of CIN-based biomarkers introduces a new layer of genomic precision, effectively “converting” standard chemotherapies into precision medicines by personalizing treatment based on tumor biology rather than just clinical presentation.

Beyond patient benefits, the economic implications of this advancement are substantial. Avoiding ineffective chemotherapy spares healthcare systems the mounting costs associated with managing drug toxicity, hospitalization, and supportive care. Furthermore, by selecting the appropriate therapeutic agents upfront, clinicians can optimize treatment efficacy, potentially improving survival rates and quality of life.

Following the promising results of the computational study, the research consortium has secured funding from the Spanish Ministry for Digital Transformation and Public Service, backed by European Union NextGenerationEU funds. This support will facilitate the crucial next phase: prospective validation of the test in hospital settings. Collaborations with Tailor Bio and Spain’s 12 de Octubre University Hospital will focus on integrating the test into routine clinical workflows through the analysis of existing patient tissue samples, aiming to demonstrate clinical utility and readiness for implementation in controlled trials by 2026.

The translational pathway from discovery to clinic, as Macintyre elaborates, is often fraught with challenges, from regulatory hurdles to validation complexities. However, the multidisciplinary synergy between computational biology, clinical oncology, and biotech innovation provides a robust foundation to overcome these obstacles, heralding a new standard in cancer treatment personalization.

The underlying patents held by the CNIO team and collaborators reflect the novel intellectual property embedded in using copy number signatures for predicting chemotherapy response and methods enhancing the accuracy of copy number calling in targeted sequencing data. These patents signify the innovative scope of the approach and its potential for commercialization and broad clinical adoption.

This development further signals a paradigm shift in cancer treatment strategies whereby genomic instability—a hallmark feature of many malignancies—is harnessed not only as a prognostic marker but also as a predictive tool to guide therapy. By elucidating the complex chromosomal landscapes within tumors, oncologists gain unprecedented insight into tumor biology, resistance mechanisms, and optimal therapeutic avenues.

The authors of the study published in “Nature Genetics” include CNIO researchers Joe Sneath Thompson and Barbara Hernando, along with Tailor Bio’s Laura Madrid, reflecting strong international collaboration. Their work emphasizes the integration of computational simulations, large-scale genomic data analysis, and clinical insights, showcasing the potential of computational oncology to resolve long-standing challenges in cancer therapeutics.

As this technology matures toward clinical implementation, its impact could be transformative, potentially benefiting hundreds of thousands of cancer patients annually worldwide. By tailoring chemotherapy regimens to individual genomic profiles, the test promises to enhance therapeutic success rates while minimizing unnecessary toxicity, effectively redefining the concept of precision medicine in oncology.

The Spanish National Cancer Research Center (CNIO) stands at the forefront of such innovations, leveraging its extensive scientific expertise and collaborative networks to translate cutting-edge genomic science into tangible patient benefits. This latest advancement embodies their commitment to improving cancer diagnosis, treatment, and ultimately, patient survival, marking a watershed moment in the fight against cancer.

Subject of Research: Human tissue samples

Article Title: Predicting resistance to chemotherapy using chromosomal instability signatures

News Publication Date: 23-Jun-2025

Web References: http://dx.doi.org/10.1038/s41588-025-02233-y

Image Credits: Laura M. Lombardía / CNIO

Keywords: Cancer research, Chemotherapy, Cancer treatments, Computational biology